An FDA advisory panel concludes that the efficacy of brexpiprazole, when started concurrently with sertraline, has not been ...

"I may have been swayed if this represented a major advance in the field," said panelist Walter Dunn, MD, PhD, of the ...

This summary covers significant health news including FDA advisers rejecting Otsuka's PTSD treatment, Getinge exceeding ...

The FDA panel voted against Otsuka's PTSD drug combination with Zoloft, questioning its efficacy. Getinge surpassed profit ...

Otsuka and Lundbeck’s data are insufficient to establish significant efficacy of Rexulti plus sertraline in PTSD, according ...

The controversial drugs are not yet approved by federal regulators, but advocates hope a NC law would allow the state to be ...

A U.S. Food and Drug Administration (FDA) advisory panel has voted overwhelmingly against the approval of Otsuka ...

The administration said it is fast-tracking clinical trials that would allow patients struggling with serious mental health ...

The head of the U.S. Department of Veterans Affairs (VA) is reiterating that he’s “very open” to expanding access to ...

Market is valued at USD 10.25 Billion in 2024 and is projected to reach a value of USD 610.1 Billion by 2035 at a CAGR ...

Proponents of reining in the largely unregulated intoxicating hemp industry in Texas shared new polling data on Wednesday ...